Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267949 | 0.87 | KMT2A (0.44) | SLC2A1KCNH2KMT2AL3MBTL1JAK2 | |
| SCHEMBL5726714 | 0.87 | SLC2A1 (0.61) | SLC2A1KCNH2 | |
| SCHEMBL5426784 | 0.84 | KMT2A (0.42) | KCNH2KMT2AL3MBTL1JAK2JAK1 | |
| SCHEMBL4878459 | 0.83 | KCNH2 (0.59) | SLC2A1KCNH2JAK2JAK1 | |
| SCHEMBL3250355 | 0.83 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1MAP4K4 | |
| SCHEMBL3254324 | 0.83 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1MAP4K4 | |
| SCHEMBL6687899 | 0.83 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1MAP4K4 | |
| SCHEMBL3250358 | 0.83 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1MAP4K4 | |
| SCHEMBL3254329 | 0.83 | SLC2A1 (0.49) | SLC2A1KCNH2JAK2JAK1MAP4K4 | |
| SCHEMBL13145843 | 0.83 | SLC2A1 (0.53) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | SLC2A1 4714/4885KCNH2 3363/4885KMT2A 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.